Cardinal Health Inc (NYSE:CAH). shares have reached an unprecedented peak, setting an all-time high of $126.15. With a market capitalization of $30.45 billion, this milestone underscores the company's robust performance and investor confidence in its growth trajectory. According to InvestingPro analysis, the stock appears slightly undervalued at current levels. Over the past year, Cardinal Health has witnessed a significant appreciation in its stock value, with a commendable 1-year change of 17.43%, while delivering even stronger returns of 26.6% in the past six months. This impressive uptrend reflects the market's positive reception to the company's strategic initiatives and its resilience in a dynamic healthcare sector. The company has maintained dividend payments for 42 consecutive years, demonstrating long-term stability. Investors are closely monitoring Cardinal Health's progress as it continues to innovate and expand its influence in the industry. For deeper insights and 15 additional ProTips about Cardinal Health, visit InvestingPro.
In other recent news, Cardinal Health has been highlighted for its sustained EBIT growth, particularly in its core ' Pharmaceutical (TADAWUL:2070) & Specialty' segment. Mizuho (NYSE:MFG) Securities initiated an Outperform rating on the company's shares, with a price target set at $139. This projection is based on a 15 times price-to-earnings ratio on the forecasted calendar year 2026 earnings per share of $9.05.
In recent developments, Cardinal Health successfully raised $2.9 billion through the public offering of senior notes. The funds are intended to partially finance the company's planned acquisitions of The GI Alliance Holdings, LLC, and Advanced Diabetes Supply Group. Furthermore, the company reported an increase in earnings per share and adjusted free cash flow expectations for fiscal year 2025, despite a decrease in total revenue.
Cardinal Health also announced plans to acquire Integrated Oncology Network for $1.1 billion. At the recent annual meeting, all 10 board nominees were elected and the executive compensation was approved. Ernst & Young LLP was ratified as the company's independent auditor for the fiscal year ending June 30, 2025. These are all part of the recent developments in the company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.